Pall — FY2014 Earnings Presentation
24 slides from Pall's earnings presentation, Aug 28, 2014
Slide 1: Q4 and Full Year FY 2014 Financial Results
Better Lives. Better Planet.SM © 2014 Pall Corporation Q4 and Full Year FY 2014 Financial Results August 28, 2014 Exhibit 99.2
Slide 2: Forward-looking statements
2 The matters discussed in this presentation contain “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. Results for the fourth quarter of fiscal year 2014 are preliminary until our Form 10-K is filed with the Securities and Exchange Commission on or befo
Slide 3: Conference Call Information
3 Conference Call Information Dial-In Toll-Free: 855.356.7268 International: 706.634.1981 Replay Toll-Free: 855.859.2056 International: 404.537.3406 Conference ID: 84648660 Internet: www.pall.com/investor
Slide 4: FY 2014 Performance vs Guidance: Delivered the Plan
4 FY 2014 Performance Guidance (as presented 8/29/13) Results Revenue Growth(1): Low-to-mid single-digit Segment Revenue Growth(1) Life Sciences: Mid-to-high single-digit Industrial: Flat Gross Margin(1): 20 − 40 basis point improvement SG&A(1): 100 basis point improvement Pro forma EP
Slide 5: Capital Allocation
5 FY14 FY13 FY12 FY11 FY10 Share Repurchase $250 $250 $121 $150 $100 Dividend 119 108 89 78 71 M&A(1) 319 22 174 - 19 Totals $688 $380 $384 $228 $190 Free Cash Flow $429 $274 $316 $269 $242 Capital Allocation Dollars in millions (1) Includes acquisition of businesses, net of cash acquired, and the a
Slide 6: Financial Overview
6 18.8% 19.8% 17.7% 18.3% 10.0% 15.0% 20.0% 25.0% Q4 Full Year +100 bps +60 bps FY 2013 FY 2014 $717 $800 $2,648 $2,789 $- $500 $1,000 $1,500 $2,000 $2,500 $3,000 Q4 Full Year +6% +10% FY 2013 FY 2014 Revenue % Growth Ex-FX Financial Overview Dollars in millions, except EPS data A reconciliation of
Slide 7: Fourth Quarter and Full Year FY 2014 Sales by Segment
7 Fourth Quarter FY 2014 Sales by Segment Full Year Life Sciences Consumables $376 / +17% Industrial Consumables $324 / +14% Industrial Systems $63 / -22% Life Sciences Systems $37 / -4% 41% 47% 7% 5% Life Sciences Consumables $1,329 / +10% Industrial Consumables $1,115 / +3% Industrial Systems $220
Slide 8: Life Sciences Segment Performance
8 56.8% 55.7% 57.8% 56.0% 0% 30% 60% 24.2% 25.4% 24.4% 24.6% 0% 30% 60% Life Sciences Segment Performance Dollars in millions. Sales and orders changes exclude FX A reconciliation of Non-GAAP Financial Measures in this presentation to their GAAP Counterparts is provided in the Appendix -110 bps FY 2
Slide 9: Industrial Segment Performance
9 Industrial Segment Performance Gross Margin Segment Margin Q4 / Full Year Process Technologies consumables: +14% / 0% Aerospace consumables: +17% / -1% Microelectronics consumables: +9% / +14% 46.3% 46.1% 46.0% 45.8% 0% 30% 60% FY 2013 FY 2014 Sales Q4 YoY Change Ex-FX Full Year YoY Change E
Slide 10: Cash Flow and Working Capital
10 Cash Flow and Working Capital YTD FY14 YTD FY13 Operating Cash Flow 504$ 384$ CapEx (75) (110) Free Cash Flow 429$ 274$ Other Significant Sources/(Uses) of Cash: Notes Payable 255$ (35)$ Proceeds from sale of assets 6 538 Dividends (119) (108) Share Repurchase (250) (250) Acquisitions of business
Slide 11: FY 2015 Outlook
11 Total Revenue Mid-to-high single-digit growth Organic low-to-mid single-digit growth Segment Revenue Life Sciences: Mid-to-high single-digit growth Industrial: Mid-to-high single-digit growth Pro Forma EPS $3.75 – $3.95 Represents growth of 9% – 15% Estimate excludes discrete items,
Slide 12: Appendix
Better Lives. Better Planet.SM © 2014 Pall Corporation Appendix
Slide 13: Appendix: Cash Flow
13 Appendix: Cash Flow Reconciliation of Non-GAAP Financial Measures Dollars in thousands Free Cash Flow FY2014 FY2013 FY2012 FY2011 FY2010 Operating cash flow $ 503,912 $ 384,459 $ 474,848 $ 429,987 $ 377,860 apital expenditures (74,737) (110,182) (158,909) (160,771) (136,313) Free cash flow 429,17
Slide 14: Appendix: Earnings from Continuing Operations
14 Appendix: Q4 and Full Year Earnings from Continuing Operations Reconciliation of Non-GAAP Financial Measures Diluted EPS from continuing operations as reported 1.08$ 0.76$ 3.25$ 2.89$ Discrete Items: ROTC after pro forma tax effect 0.08 0.14 0.32 0.28 Tax Adjustments (0.06) - (0.14) (0.09) I tere
Slide 15: Appendix: Q4 Operating Profit
15 Appendix: Q4 Operating Profit Reconciliation of Non-GAAP Financial Measures Q4 FY14 Q4 FY13 Life Sciences segment profit 104,889$ 85,757$ Industrial segment profit 72,449 68,075 Total segment profit 177,338$ 153,832$ General corporate expenses (19,166) (19,377) Operating profit 158,172$ 134,455$
Slide 16: Appendix: Full Year Operating Profit
16 Appendix: Full Year Operating Profit Reconciliation of Non-GAAP Financial Measures Full Year FY14 Full Year FY13 Life Sciences segment profit 357,129$ 319,271$ Industrial segment profit 219,172 214,798 Total segment profit 576,301$ 534,069$ General corporate expenses (67,200) (66,640) Operating p
Slide 17: Appendix: Q4 Life Sciences Sales By Market & Technology
17 Appendix: Q4 Life Sciences Sales By Market & Technology Reconciliation of Non-GAAP Financial Measures Q4 FY14 Q4 FY14 Estimated Impact of FX Q4 FY14 Estimate Excluding FX Q4 FY13 % Change Excluding FX Consumables Sales: BioPharmaceuticals 267,075$ 5,442$ 261,633$ 215,211$ 21.6% Food & Beverage 51
Slide 18: Appendix: Full Year Life Sciences Sales By Market & Technology
18 Appendix: Full Year Life Sciences Sales By Market & Technology Reconciliation of Non-GAAP Financial Measures Full Year FY14 Full Year FY14 Estimated Impact of FX Full Year FY14 Estimate Excluding FX Full Year FY13 % Change Excluding FX Consumables Sales: BioPharmaceuticals 917,542$ 5,569$ 911,973
Slide 19: Appendix: Q4 Industrial Sales By Market & Technology
19 Appendix: Q4 Industrial Sales By Market & Technology Reconciliation of Non-GAAP Financial Measures Q4 FY14 Q4 FY14 Estimated Impact of FX Q4 FY14 Estimate Excluding FX Q4 FY13 % Change Excluding FX Consumables Sales: Process Technologies 173,972$ 802$ 173,170$ 151,299$ 14.5% Aerospace 70,299 1,03
Slide 20: Appendix: Full Year Industrial Sales By Market & Technology
20 Appendix: Full Year Industrial Sales By Market & Technology Reconciliation of Non-GAAP Financial Measures Full Year FY14 Full Year FY14 Estimated Impact of FX Full Year FY14 Estimate Excluding FX Full Year FY13 % Change Excluding FX Consumables Sales: Process Technologies 576,062$ (5,969)$ 582,03
Slide 21: Appendix: Q4 Orders by Technology
21 Appendix: Q4 Orders by Technology Reconciliation of Non-GAAP Financial Measures Q4 FY14 Q4 FY14 Estimated Impact of FX Q4 FY14 Estimate Excluding FX Q4 FY13 % Change Excluding FX Life Sciences Orders: Consumables 360,304$ 6,634$ 353,670$ 315,043$ 12.3% Systems 32,145 789 31,356 24,917 25.8% Life
Slide 22: Appendix: Full Year Orders by Technology
22 Appendix: Full Year Orders by Technology Reconciliation of Non-GAAP Financial Measures Full Year FY14 Full Year FY14 Estimated Impact of FX Full Year FY14 Estimate Excluding FX Full Year FY13 % Change Excluding FX Life Sciences Orders: Consumables 1,371,405$ 4,334$ 1,367,071$ 1,225,836$ 11.5% Sys
Slide 23: Appendix: Q4 Organic Sales Growth by Segment
23 Appendix: Q4 Organic Sales Growth by Segment Reconciliation of Non-GAAP Financial Measures Q4 FY14 Q4 FY13 Percent Change Q4 FY14 Impact of FX % Change Excluding FX Life Sciences Sales: Organic 391,812$ 354,145$ 10.6% 7,419$ 8.5% Acquisitions 20,846 - - Total Life Sciences Sales 412,658$ 354,145$
Slide 24: Appendix: Full Year Organic Sales Growth by Segment
24 Appendix: Full Year Organic Sales Growth by Segment Reconciliation of Non-GAAP Financial Measures Full Year FY14 Full Year FY13 Percent Change Full Year FY14 Impact of FX % Change Excluding FX Life Sciences Sales: Organic 1,403,872$ 1,309,375$ 7.2% 5,591$ 6.8% Acquisitions 49,797 - - Total Life S